---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010223"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:56:22.036376+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's

## Summary
- PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.
- CSF levels dose-proportional at days 3 and 29; lowest dose >100-fold molar excess over expected oligomers.
- CSF half-life ~25 days, supportive of monthly dosing.
- Company plans to initiate Phase 1b in Alzheimer's patients in H2 2024.
- Full dataset to be presented at a medical meeting in H2 2024.

## SEC filing metadata
- accession: 0001558370-24-010223
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/0001558370-24-010223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024010223/pmn-20240726x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010223
- JSON: https://secwatch.observer/filing/0001558370-24-010223.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.